Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$200.00K$200.00Kderived+14.3% vs Q4 2024 Net Income-$5.16M-$5.16MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$5,198,000N/M Operating Cash Flowderived-$4,615,000N/M Free Cash Flowderived-$4,616,000N/M Margins · derivedOperating margin-2599.0%−651.0 pt vs Q4 2024
Net margin-2581.5%+1863.1 pt vs Q4 2024
ended Jun 30, 2025 · filed Sep 5, 2025 · 67 d after period end